← Back to Search

S-217622 for COVID-19 (SCORPIO-HR Trial)

Verified Trial
Phase 3
Recruiting
Research Sponsored by Shionogi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Feeling feverish
- Body pain or muscle pain or aches
Must not have
Known allergy/sensitivity or any hypersensitivity to components of S-217622 or placebo for S-217622
Are you 65 years or older?
Timeline
Screening 1 day
Treatment Varies
Follow Up 29 days
Awards & highlights

SCORPIO-HR Trial Summary

This trial is testing a new drug against placebo to see if it is effective in treating people with COVID-19 who are not expected to benefit from standard care.

Who is the study for?
Adults with mild to moderate COVID-19 symptoms, who started experiencing them within the last 3 days, can join this trial. They must be under 65 years old and not hospitalized for their current infection. Participants should not have received other investigational treatments for this episode of COVID-19 or be on medications that could interfere with the study drug.Check my eligibility
What is being tested?
The trial is testing S-217622 against a placebo in non-hospitalized adults to see if it's effective in treating early-stage COVID-19. Participants will randomly receive either the study medication or a placebo shortly after symptom onset.See study design
What are the potential side effects?
Potential side effects are not detailed here but may include reactions similar to those seen with other antiviral drugs such as nausea, diarrhea, headaches, or allergic reactions.

SCORPIO-HR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been feeling feverish.
Select...
I experience body or muscle pain.
Select...
I am experiencing diarrhea.
Select...
I experience nausea.
Select...
I have been experiencing vomiting.
Select...
I experience headaches.
Select...
I have a sore throat.
Select...
I have a blocked or stuffy nose.
Select...
I experience nausea.
Select...
I am experiencing symptoms similar to COVID-19.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
You have an allergy or sensitivity to any of the ingredients in S-217622 or the placebo used in the study.
Select...
I am 65 years old or older.

SCORPIO-HR Trial Timeline

Screening ~ 1 day
Treatment ~ Varies
Follow Up ~29 days
This trial's timeline: 1 day for screening, Varies for treatment, and 29 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Median Time to Sustained Symptom Resolution
Secondary outcome measures
Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score
Change From Baseline in Post-Acute COVID-19 Questionnaire
Change From Baseline in Quantitative log10 SARS-CoV-2 RNA Levels by Polymerase Chain Reaction (PCR) on Nasopharyngeal (NP) Swab at Day 4
+16 more

SCORPIO-HR Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: S-217622Experimental Treatment1 Intervention
S-217622 will be administered orally for 5 days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo matching to S-217622 will be administered orally for 5 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
S-217622
2022
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

ShionogiLead Sponsor
115 Previous Clinical Trials
39,261 Total Patients Enrolled
2 Trials studying COVID-19
12,102 Patients Enrolled for COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,266 Previous Clinical Trials
5,478,392 Total Patients Enrolled
78 Trials studying COVID-19
290,208 Patients Enrolled for COVID-19

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT05305547 — Phase 3
COVID-19 Research Study Groups: Placebo, S-217622
COVID-19 Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05305547 — Phase 3
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT05305547 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the harmful effects of S-217622?

"S-217622 has undergone Phase 3 trials, meaning that there is both some efficacy data as well as multiple rounds of safety data. Based on this, our team at Power has given it a safety rating of 3."

Answered by AI

Are enrolling any more people in this experiment?

"The trial is open for recruitment, as shown by the information available on clinicaltrials.gov. This includes the initial posting date of 8/3/2022 and the most recent update of 11/1/2022."

Answered by AI

In how many cities is this research project being conducted?

"This trial has 22 enrolling patients at locations such as Progressive Clinical Research in Bountiful, SVG Clinical in Las Vegas, and Infusion Associates in Grand Rapids."

Answered by AI

Who else is applying?

What state do they live in?
Washington
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
What site did they apply to?
Burke Primary Care
Invictus Clinical Research Group, LLC
Other
Quantum Clinical Trials

Why did patients apply to this trial?

Want to help find something that works. De momento no e probado ningun medicamento.
PatientReceived no prior treatments
Given my age, I would like to help with Covid research. I have attempted multiple other OTC drugs for my symptoms over these past 5 days and nothing's helped.
PatientReceived no prior treatments

How responsive is this trial?

Most responsive sites:
  1. Quantum Clinical Trials: < 24 hours
Average response time
  • < 2 Days
Typically responds via
Phone Call
~774 spots leftby Mar 2025